Ultrasound and ROS-responsive nanodroplets inhibit TCA cycle in hepatocellular carcinoma

ROS- and US-responsive targeted sGTND was constructed. sGTND possesses excellent biocompatibility and exhibits ROS-responsive drug release. sGTND responds to US to achieve UTMD effects and CEUI imaging. sGTND/UTMD combination inhibits TCA cycle through NRF2 activation and G6PD inhibition.